Predictive Oncology (NASDAQ: POAI) launched a program designed to advance the oncology drug-development initiatives with academic and research institutions. The program, called ACE, partners with early-stage academic and research institutions to assist in advancing their efforts and focus on drug discovery. The program provides access to POAI’s PEDAL platform, which brings together active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results. That program works to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations. “We designed the program to give researchers the opportunity to explore an otherwise unreachable experimental space,” said Predictive Oncology senior vice president of drug discovery operations Arlette Uihlein, MD, in the press release. “Our goal is to help shorten the time necessary to identify impactful drug candidates and circumvent the funding limitations that might prevent those drugs from reaching the clinic. . . . We can additionally help them re-evaluate small molecules that would not have had sufficient traction to reach the market.”
To view the full press release, visit https://ibn.fm/xQ6Yw
About Predictive Oncology Inc.
Predictive Oncology, a science-driven company on the leading edge of oncology drug discovery, offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of more than 150,000 tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
